Researchers reveal how regular alcohol use impairs the effectiveness of cancer immunotherapy

Researchers have figured out how regular alcohol use impairs the effectiveness of a popular form of cancer immunotherapy, according to their analysis of mouse models and data from a patient cohort. Their discoveries are some of the first to establish how alcohol disrupts anti-cancer immunity at the molecular level, and also point to several therapeutic approaches to restore the effectiveness of immunotherapy.

Studies have shown that alcohol consumption can weaken the immune system's ability to fight off viruses, bacteria, and tumor cells. Although clinicians often caution patients with cancer to avoid alcohol consumption, recent studies have shown that as many as 76.4% of patients still drink alcohol. Therefore, medical societies have called for more research to investigate how alcohol impacts treatment outcomes in patients. Here, Kristen Gilley and colleagues examined the impact of alcohol consumption in mouse models of lung and bladder cancer.

They gave the mice a moderate-to-heavy amount of ethanol – equivalent to three to six drinks a day in a person – while administering anti-PD-1 antibodies, a form of immune checkpoint inhibition. The alcohol reduced the effectiveness of the treatment by roughly 50% and raised the risk of tumor relapse, primarily by suppressing tumor-infiltrating and memory T cells while boosting other T cells that carry an immune-suppressing receptor named TIGIT. However, targeting TIGIT with antibodies restored the efficacy of anti-PD-1 antibodies in the rodents.

Gilley et al. then retrospectively studied a cohort of patients with skin, lung, bladder, or head and neck cancer, and found that people who self-reported having eight or more drinks a week had poorer survival rates after starting immune checkpoint inhibition. "This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention," Gilley et al. write, adding that incorporating patient's alcohol use into cancer databases could shed light on its effect on other types of cancer therapies.

Source:
Journal reference:

Gilley, K. N., et al. (2026). Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity. Science Signaling. DOI: 10.1126/scisignal.aef1375. https://www.science.org/doi/10.1126/scisignal.aef1375

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds earlier endometrial cancer diagnoses among Native American and Hispanic women